(Reuters) – The COVID-19 vaccine developed by Ocugen Inc’s Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.
(Reporting by Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.)
